CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – Batch 3 & 4 [REPOST of FEC topics and Cycle 1 topics for Economic Assessments]

Published 16 January 2025 This call consists of prioritized health technology topics that underwent clinical assessment under the HTA general track and are proceeding to economic assessment which includes economic evaluation (EE), budget impact analysis (BIA), and household financial impact (HFI) analysis to assess both the value for money of a health technology and its continue reading : CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – Batch 3 & 4 [REPOST of FEC topics and Cycle 1 topics for Economic Assessments]

HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution

Update as of 25 November 2024 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution ended on 22 November 2024 without valid appeals received, this continue reading : HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution

HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir

Update as of 06 November 2024 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir ended on 05 November 2024 without appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted to the Secretary of continue reading : HTA Council Preliminary Recommendation on Dapivirine Vaginal Ring, Donepezil Hydrochloride, Tenofovir/Lamivudine/Dolutegravir and Tenofovir + Lamivudine in combination with Dolutegravir

HTA Council Preliminary Recommendation on Citicoline For Ischemic Stroke

Update as of 10 October 2024 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Citicoline for Ischemic Stroke ended on 09 October 2024 without appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted to the Secretary of Health for decision. Published 25 continue reading : HTA Council Preliminary Recommendation on Citicoline For Ischemic Stroke

HTA Council Preliminary Recommendation on Pneumococcal Conjugate Vaccines (PCV) for infants less than 1 year old and children aged 13 to 23 months for catch-up immunization

Update as of 10 October 2024 : The public consultation and appeals period for the HTA Council Preliminary Recommendation on Pneumococcal Conjugate Vaccines (PCV) for infants less than 1 year old and children aged 13 to 23 months for catch-up immunization ended on 09 October 2024. Since there were valid appeals received, re-evaluation is currently continue reading : HTA Council Preliminary Recommendation on Pneumococcal Conjugate Vaccines (PCV) for infants less than 1 year old and children aged 13 to 23 months for catch-up immunization